Quipt Announces Execution of LOI to Acquire Leader in Comprehensive Respiratory Care Within the Long-Term Care Setting With Approximately $14 Million in Annualized Revenue and $1 Million in Net Income

NEXT STORY
AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia
PREV STORY
LIDDS Interim report January – September 2021
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Quipt Announces Execution of LOI to Acquire Leader in Comprehensive Respiratory Care Within the Long-Term Care Setting With Approximately $14 Million in Annualized Revenue and $1 Million in Net Income

NEXT STORY
AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia
PREV STORY
LIDDS Interim report January – September 2021
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Clinical Trial Materials & Supplies Market by Service, Clinical Trial Type, Phase, Medical Specialty, End-user and Region – Forecast to 2025

author_avatar
NASDAQ Market News

Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMA

author_avatar
NASDAQ Market News

Cara Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

author_avatar
NASDAQ Market News